The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized phase Ⅱ trial of uracil/tegafur and cisplatin versus pemetrexed and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage Ⅲ non-squamous non-small-cell lung cancer: NJLCG1001.
 
Kana Watanabe
No Relationships to Disclose
 
Yukihiro Toi
Honoraria - Bristol-Myers Squibb-Ono Pharmaceutical
 
Atsushi Nakamura
Honoraria - AstraZeneca; Chugai Pharma; MSD
Speakers' Bureau - AstraZeneca
 
Tatsuro Fukuhara
Honoraria - AstraZeneca
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Ono Pharmaceutical (Inst)
 
Ryosuke Chiba
No Relationships to Disclose
 
Masachika Akiyama
No Relationships to Disclose
 
Jun Sakakibara-Konishi
No Relationships to Disclose
 
Hisashi Tanaka
No Relationships to Disclose
 
Naruo Yoshimura
No Relationships to Disclose
 
Eisaku Miyauchi
No Relationships to Disclose
 
Taku Nakagawa
No Relationships to Disclose
 
Ryotaro Igusa
No Relationships to Disclose
 
Hiroyuki Minemura
Research Funding - Boehringer Ingelheim Seiyaku
 
Yoshiaki Mori
No Relationships to Disclose
 
Keisuke Fujimoto
No Relationships to Disclose
 
Haruo Matsushita
No Relationships to Disclose
 
Fumiaki Takahashi
No Relationships to Disclose
 
Akira Inoue
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly Japan; Mundipharma; Nihonkayaku; Novartis; Ono Pharmaceutical; Pfizer; Shionogi; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Lilly Japan; MSD
Research Funding - Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Shionogi (Inst)
 
Shunichi Sugawara
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Kyowa Hakko Kirin; Lilly; MSD K.K; Nippon Boehringer Ingelheim; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
 
Makoto Maemondo
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Lilly Japan (Inst); MSD (Inst); Novartis (Inst); Sanofi (Inst)